Rxsight

Rxsight LT Debt/Equity

The Long-Term Debt to Equity Ratio of Rxsight (RXST) as of Nov 22, 2026 is 0.45. In the previous year, Long-Term Debt to Equity Ratio was 0.31 — a change of 42.32% (higher).

LT Debt/Equity

0.45

YoY

42.32%

Last updated:

Long-Term Debt to Equity Ratio of Rxsight is 2022 0.45 . Long-Term Debt to Equity Ratio of Rxsight was 2021 0.31 . It decreases by 42.32% higher compared to the previous year.

The Rxsight LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2020
-0.08 USD
Jan 1, 2021
0.31 USD
Jan 1, 2022
0.45 USD
The Rxsight LT Debt/Equity history
YEARLT Debt/EquityYoY
0.45+42.32%
0.31-482.85%
-0.08—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rxsight Stock analysis

What does Rxsight do? Rxsight Inc is an innovative company that specializes in developing innovative solutions for eye treatments. The company aims to make a positive contribution to the quality of life for patients suffering from eye problems. Rxsight Inc was founded in 2008 by Jim Taylor, who had previously worked in computer graphics at Pixar Animation Studios and was now involved in new technologies for ophthalmology. The business model of Rxsight Inc is based on the development and marketing of medical products that improve the treatment of eye diseases. The company focuses on the field of dynamic ophthalmology, which aims to improve treatment options for eye diseases by focusing on the influence of eye movements and changes in pupil size. Rxsight Inc is divided into various divisions, with an important division focusing on research and development of products that can improve the treatment of eye diseases. The company invests heavily in developing innovative products. Additionally, Rxsight Inc is also involved in the manufacturing and marketing of medical products. Rxsight Inc's products include special contact lenses that can be individually customized through precise measurement of the eye lens. These contact lenses can help patients achieve better visual quality after eye surgery. Rxsight Inc also offers certain measuring devices that are used for measuring and analyzing eye movements and pupil size. Another important product from Rxsight Inc is the "Light Adjustable Lens System," which is a system for intraocular lenses that operates based on feedback from light and energy. The system allows for an individualized process for adjusting the strength of intraocular lenses. With the "Light Adjustable Lens System," patients can achieve significantly improved visual quality after cataract surgery. Overall, Rxsight Inc has established itself as an innovative company in ophthalmology. The company focuses on research and development to provide new technologies for the treatment of eye diseases. Rxsight Inc emphasizes dynamic ophthalmology to consider the influence of eye movements and pupil size in the therapy of eye diseases. With its products, Rxsight Inc makes an important contribution to improving the visual quality of patients. Rxsight is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rxsight stock

Long-Term Debt to Equity Ratio of Rxsight is 0.45 in 2022.

Long-Term Debt to Equity Ratio of Rxsight changed from 0.31 to 0.45, representing a 42.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Rxsight since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Rxsight with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Rxsight

All Key Metrics — Rxsight